Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder
- PMID: 18833573
- DOI: 10.1002/da.20505
Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder
Abstract
Objective: To characterize the spectrum of clinical outcomes achieved with depression treatment and the associated impact on quality of life (QOL), functional status, overall well-being, health-care costs, and productivity.
Sources: Electronic databases including Medline were searched for English language sources between 1995 and 2007 using key words of depression, nonresponse, partial response, and remission and QOL, functional status, utility, cost, and productivity.
Study selection: Relevant abstracts were obtained for 488 references and full-text articles were reviewed that included primary data and compared outcomes by treatment response. Data were abstracted from 26 full-text articles.
Data abstraction: Detailed evidence tables were prepared with the relevant data as well as information on the study design. All data abstracted were checked for accuracy. synthesis: Treatment remitters and partial responders reported clinically and statistically significant improvements in QOL, functional status, and overall well-being compared to nonresponders. Annual health-care costs and productivity losses were significantly lower for remitters and partial responders compared to nonresponders.
Conclusions: The reduced disease burden for remitters and partial responders compared to nonresponders indicates that new treatment strategies that improve the rates of response/remission with initial treatment might have value to patients and to society.
(c) 2008 Wiley-Liss, Inc.
Similar articles
-
The human cost of not achieving full remission in depression.Can J Psychiatry. 2004 Mar;49(3 Suppl 1):10S-16S. Can J Psychiatry. 2004. PMID: 15147032 Review.
-
Understanding the burden of depression.J Clin Psychiatry. 2011 Jun;72(6):e19. doi: 10.4088/JCP.10126tx1c. J Clin Psychiatry. 2011. PMID: 21733472
-
Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.Aust N Z J Psychiatry. 2009 Jun;43(6):539-47. doi: 10.1080/00048670902873664. Aust N Z J Psychiatry. 2009. PMID: 19440886 Review.
-
Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden.Can J Psychiatry. 2001 Jun;46 Suppl 1:13S-20S. Can J Psychiatry. 2001. PMID: 11441768
-
The functioning and quality of life of depressive patients with 12 weeks of psychiatric care.J Med Assoc Thai. 2005 Sep;88(9):1261-6. J Med Assoc Thai. 2005. PMID: 16536114
Cited by
-
The role of dopaminergic agents in improving quality of life in major depressive disorder.Curr Psychiatry Rep. 2009 Dec;11(6):503-8. doi: 10.1007/s11920-009-0076-z. Curr Psychiatry Rep. 2009. PMID: 19909674 Review.
-
Is meat consumption associated with depression? A meta-analysis of observational studies.BMC Psychiatry. 2017 Dec 28;17(1):409. doi: 10.1186/s12888-017-1540-7. BMC Psychiatry. 2017. PMID: 29282023 Free PMC article.
-
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.BMC Psychiatry. 2019 Nov 29;19(1):375. doi: 10.1186/s12888-019-2359-1. BMC Psychiatry. 2019. PMID: 31783823 Free PMC article.
-
Effects of Electroacupuncture on Chronic Unpredictable Mild Stress Rats Depression-Like Behavior and Expression of p-ERK/ERK and p-P38/P38.Evid Based Complement Alternat Med. 2015;2015:650729. doi: 10.1155/2015/650729. Epub 2015 Aug 20. Evid Based Complement Alternat Med. 2015. PMID: 26366182 Free PMC article.
-
Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095. Int J Neuropsychopharmacol. 2019. PMID: 30508090 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources